Biogen Inc. reported third-quarter total revenue of $2.8 billion, an 11% increase year-over-year, driven by a 49% surge in its Growth Portfolio to $1.26 billion. The company posted a GAAP diluted loss per share of $(0.14), primarily due to $284 million in acquired IPR&D and milestone expenses related to the RayThera acquisition, while Non-GAAP diluted EPS was $2.62. Biogen raised its full-year 2026 Non-GAAP diluted EPS guidance range lower end from $12.00 to $12.20, citing ongoing business strength and favorable Apellis dilution dynamics. The biotechnology firm develops and commercializes treatments for neurological and rare diseases.
